Literature DB >> 17220377

A murine respiratory-inducing niche displays variable efficiency across human and mouse embryonic stem cell species.

Mark Denham1, Brock J Conley, Fredrik Olsson, Lerna Gulluyan, Timothy J Cole, Richard Mollard.   

Abstract

Human embryonic stemlike cells (hESCs) are pluripotent cells derived from blastocysts. Differentiating hESCs into respiratory lineages may benefit respiratory therapeutic programs. We previously demonstrated that 24% of all mouse embryonic stem cell (mESC) derivatives cocultured with embryonic day 11.5 (E11.5) mouse lung rudiments display immunoreactivity to the pneumonocyte II specific marker surfactant-associated protein C (Sftpc). Here we further investigate the effects of this inductive niche in terms of its competence to induce hESC derivative SFTPC immunoreactivity and the expression of other markers of terminal lung secretory units. When hESCs were cocultured as single cells, clumps of approximately 10 cells or embryoid bodies (EBs), hESC derivatives formed pan-keratin-positive epithelial tubules at high frequency (>30% of all hESC derivatives). However, human-specific SFTPC immunoreactivity associated with tubule formation only at low frequency (<0.1% of all hESC derivatives). Human-specific SFTPD and secretoglobin family 1A member 1 (SCGB1A1, also known as CC10) transcripts were detected by PCR after prolonged culture. Expression of other terminal lung secretory unit markers (TITF1, SFTPA, and SFTPB) was not detected at any time point analyzed. On the other hand, hESC derivatives cultured as plated EBs in media previously demonstrated to induce Sftpc expression in isolated mouse fetal tracheal epithelium expressed all terminal lung secretory unit markers examined. mESCs and hESCs thus display fundamental differences in their response to the E11.5 mouse lung inductive niche, and these data provide an important step in the delineation of signaling mechanisms capable of efficiently inducing hESC differentiation into terminal secretory units of the lung.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17220377     DOI: 10.1152/ajplung.00440.2006

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  4 in total

Review 1.  Stem cells and cell therapies in lung biology and lung diseases.

Authors:  Daniel J Weiss; Jay K Kolls; Luis A Ortiz; Angela Panoskaltsis-Mortari; Darwin J Prockop
Journal:  Proc Am Thorac Soc       Date:  2008-07-15

Review 2.  Embryonic stem cells as a source of pulmonary epithelium in vitro and in vivo.

Authors:  Helen J Rippon; Síle Lane; Mingde Qin; N-Siti Ismail; Michael R Wilson; Masao Takata; Anne E Bishop
Journal:  Proc Am Thorac Soc       Date:  2008-08-15

3.  Stem cells and cell therapies in lung biology and lung diseases.

Authors:  Daniel J Weiss; Ivan Bertoncello; Zea Borok; Carla Kim; Angela Panoskaltsis-Mortari; Susan Reynolds; Mauricio Rojas; Barry Stripp; David Warburton; Darwin J Prockop
Journal:  Proc Am Thorac Soc       Date:  2011-06

4.  Intravenous insulin therapy during lung resection does not affect lung function or surfactant proteins.

Authors:  Zdenek Ručka; Irena Koutná; Lenka Tesařová; Michaela Potěšilová; Stanislav Stejskal; Pavel Simara; Petr Vaňhara; Jan DoleŽel; Vaclav Zvoníček; Oldřich Coufal; Ivan Capov
Journal:  BMC Pulm Med       Date:  2014-10-02       Impact factor: 3.317

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.